ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer

June 28, 2013

Genetic Testing: No Easy Answers To Public Questions

May 15, 1998

False-Positive Mammograms Can Indicate Higher Cancer Risk

April 27, 2012

Radiotherapy In Combination With Zometa Provide Pain Control For Advanced Myeloma

February 27, 2004

Hait To Take Office As AACR President, DuBois Is President-Elect.

March 30, 2007

NCI Cooperative Group, Cancer Center Trials Listed

October 31, 2008